# Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction

> **NCT03165292** · PHASE2 · TERMINATED · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 34 (actual)

## Conditions studied

- Very High Risk Neuroblastoma

## Interventions

- **RADIATION:** mIBG
- **DRUG:** Topotecan
- **DRUG:** Thiotepa
- **PROCEDURE:** Autologous stem cell transplant

## Key facts

- **NCT ID:** NCT03165292
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-01
- **Primary completion:** 2023-08-28
- **Final completion:** 2024-03-28
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** The Sponsor has been notified of an interruption in the international supply, and there is a possibility that 131I-mlBG would be unavailable to patients randomised to arm A of the trial
- **Last updated:** 2025-09-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03165292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03165292, "Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03165292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*